Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial
Authors:
Open Access
- 1 March 2000
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 82 (6) , 1138-1144
Abstract
Intraperitoneal treatment with interferon-γ (IFN-γ) has been shown to achieve surgically documented responses in the second-line therapy of ovarian cancer. To assess its efficacy in the first-line therapy, we conducted a randomized controlled trial with 148 patients who had undergone primary surgery for FIGO stage Ic–IIIc ovarian cancer. In the control arm women received 100 mg m–2cisplatin and 600 mg m–2cyclophosphamide, the experimental arm included the above regimen with IFN-γ 0.1 mg subcutaneously on days 1, 3, 5, 15, 17 and 19 of each 28-day cycle. Progression-free survival at 3 years was improved from 38% in controls to 51% in the treatment group corresponding to median times to progression of 17 and 48 months (P = 0.031, relative risk of progression 0.48, confidence interval 0.28–0.82). Three-year overall survival was 58% and 74% accordingly (n.s., median not yet reached). Complete clinical responses were observed in 68% with IFN-γ versus 56% in controls (n.s.). Toxicity was comparable in both groups except for a mild flu-like syndrome, experienced by most patients after administration of IFN-γ. Thus, with acceptable toxicity, the inclusion of IFN-γ in the first-line chemotherapy of ovarian cancer yielded a benefit in prolonging progression-free survival. © 2000 Cancer Research CampaignKeywords
This publication has 24 references indexed in Scilit:
- CELLULAR RESPONSES TO INTERFERON-γAnnual Review of Immunology, 1997
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Interferon-γ: Biology and Role in Pathogenesis1996
- Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFNγ receptorsImmunity, 1994
- Modulation of cisplatin cytotoxicity by human recombinant interferon-γ in human ovarian cancer cell linesEuropean Journal of Cancer, 1994
- Anti‐tumor and immunomodulatory activity of intraperitoneal IFN‐γ in ovarian carcinoma patients with minimal residual tumor after chemotherapyInternational Journal of Cancer, 1992
- Effect of Prior Cancer Chemotherapy on Human Tumor-Specific Cytotoxicity In Vitro in Response to Immunopotentiating Biologic Response ModifiersJNCI: Journal of the National Cancer Institute, 1991
- A Phase II Study of the Efficacy of Recombinant Interferon Gamma in Relapsing Ovarian AdenocarcinomaAmerican Journal of Clinical Oncology, 1988
- Interferon-γ for the treatment of metastatic renal cancer: Dose-dependent stimulation and downregulation of beta2 microglobulin and neopterin responsesImmunobiology, 1987
- Interferon-γ is required in activation of macrophages for tumor cytotoxicityCellular Immunology, 1983